Endocrinology

Bariatric surgery may be the go-to strategy for NASH in the obese

Elvira Manzano, 2 days ago

Bariatric surgery significantly lowers the risk of major adverse liver outcomes and major adverse cardiovascular events (MACE) – the dual primary endpoints – in obese patients with biopsy-driven nonalcoholic steatohepatitis (NASH) in the SPLENDOR* study.

High acute-to-chronic glycaemic ratio tied to worse prognosis in T2D patients with COVID-19

5 days ago

Type 2 diabetes (T2D) patients with COVID-19 who have elevated acute-to-chronic (A/C) glycaemic ratio are at increased risk of adverse outcomes, including in-hospital mortality, intensive care unit (ICU) admission, and mechanical ventilation, a study has found.

Amphilimus-eluting stents: As good as zotarolimus-eluting stents in patients with diabetes?

Roshini Claire Anthony, 5 days ago

The use of amphilimus-eluting stents (AES) in patients with diabetes mellitus undergoing percutaneous revascularization was less likely to result in target lesion or target vessel failure compared with zotarolimus-eluting stents (ZES) at 1 year, according to findings of the SUGAR trial presented at TCT 2021.

EMPEROR-Preserved: The first successful trial to improve outcomes in HFpEF

18 Nov 2021

Heart failure with preserved ejection fraction (HFpEF) represents a significant unmet medical need. The EMPEROR-Preserved trial aimed to assess the impact of empagliflozin on cardiovascular outcomes in patients with HFpEF. On 27 August 2021, during the hotline session of the 2021 ESC Virtual Congress, the main results of the EMPEROR-Preserved trial were presented by Professor Stefan Anker, principal investigator of the study, and heart failure specialist at Charité Berlin, Germany.

Clinical benefits of flash glucose monitoring with FreeStyle Libre™

15 Sep 2021

Various studies have shown the beneficial effects of the FreeStyle Libre™ flash glucose monitoring system for the continuous monitoring of glucose levels in type 1 and type 2 diabetes (T1D and T2D) patients. While clinical trials have demonstrated a reduced time in hypoglycaemia, fewer hypoglycaemic events per day, and significant reduction in glycated haemoglobin (HbA1c), real-world data have shown improved glycaemic control in these patients.

Optimising glycaemic control with FreeStyle Libre™ for better patient management

15 Sep 2021

The FreeStyle Libre™ flash glucose monitoring system includes a sensor which automatically measures and continuously stores up to 8 hours of glucose readings, allowing patients to monitor their glucose levels without the need for painful finger pricks. Physicians play an important role in reviewing and analysing glucose data that is available through LibreView to support patient management.

Continuous glucose monitoring versus self-monitoring of blood glucose: A healthcare professional’s perspective

26 Aug 2021

Technological advancements have improved glucose monitoring and diabetes care, as well as empowered patients in self-care. The introduction of continuous glucose monitoring systems (CGM), such as the Abbott FreeStyle Libre^TM, offers patients an alternative and additional advantages to self-monitoring of blood glucose (SMBG).

Navigating the CPP patient journey – case-based discussion for nurses

06 May 2021

In a webinar held on 27 March 2021, paediatric endocrinology nurses Karen Blair, Kate Davies, and Siti Zarina Yaakop shared insights and clinical experience based on their frontline roles in caring for patients with central precocious puberty (CPP) and supporting their family members.

Trimetazidine new formulation redefining angina control in daily practice

12 Mar 2021

Chronic coronary syndrome (CCS) remains a leading cause of death and disability worldwide. The dual goals of CCS management is to prevent future cardiac events, such as myocardial infarction and death, and to reduce ischaemia and relieve angina symptoms, says Prof Peter Yan, consultant cardiologist and medical director, Peter Yan Cardiology Clinic, Gleneagles Medical Centre, Singapore, during a Servier-sponsored virtual symposium.

Bempedoic acid improves lipid, glycaemic parameters regardless of metabolic status

Audrey Abella, 22 Nov 2021

Data presented at AHA 2021 demonstrated the efficacy and safety of bempedoic acid for improving lipid and glycaemic parameters and hsCRP irrespective of metabolic status.

Automatic retinal image analysis identifies diabetes early with high sensitivity

Kanas Chan, 15 Nov 2021

Screening of undiagnosed diabetes can be performed effectively with an automatic retinal image analysis (ARIA) technology developed by researchers at the Chinese University of Hong Kong (CUHK), instead of a finger-prink test.

Bamlanivimab + etesevimab combo reduces COVID-19-related hospitalization, any-cause death in high-risk patients

Elaine Soliven, 29 Oct 2021

The combination of bamlanivimab and etesevimab reduces the risk of COVID-19-related hospitalization and any-cause death in high-risk ambulatory patients, particularly those with diabetes, according to the BLAZE-1* study presented at EASD 2021.

High-dose semaglutide improves glucose metabolism outcomes in overweight/obese patients with T2D

Elaine Soliven, 27 Oct 2021

Treatment with a higher dose of semaglutide led to significantly improved glucose metabolism outcomes in patients with overweight/obesity and type 2 diabetes (T2D) compared with a lower dose of semaglutide or placebo, according to the STEP* 2 trial presented at EASD 2021.

fructose consumption tied to more liver fat

Fructose from fruit juice, SSBs tied to higher liver fat content

Audrey Abella, 13 Oct 2021

The consumption of fructose from fruit juice and sugar sweetened beverages (SSBs), but not from fruit, is associated with higher intrahepatic lipid (IHL) content, according to data from a cross-sectional study presented at EASD 2021.